iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) was the recipient of some unusual options trading on Monday. Investors bought 6,728 put options on the stock. This represents an increase of approximately 188% compared to the typical daily volume of 2,340 put options.

iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) opened at 340.48 on Thursday. iShares Nasdaq Biotechnology Index Fund has a 52 week low of $246.71 and a 52 week high of $340.92. The stock’s 50 day moving average price is $326.47 and its 200 day moving average price is $307.57.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Wednesday, September 27th were paid a $0.119 dividend. This represents a $0.48 annualized dividend and a dividend yield of 0.14%. The ex-dividend date was Tuesday, September 26th.

Several institutional investors have recently made changes to their positions in IBB. First Trust Advisors LP lifted its stake in shares of iShares Nasdaq Biotechnology Index Fund by 11.7% in the 1st quarter. First Trust Advisors LP now owns 3,408 shares of the financial services provider’s stock valued at $999,000 after purchasing an additional 358 shares during the last quarter. Sei Investments Co. lifted its stake in shares of iShares Nasdaq Biotechnology Index Fund by 297.0% in the 1st quarter. Sei Investments Co. now owns 401 shares of the financial services provider’s stock valued at $118,000 after purchasing an additional 300 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new position in shares of iShares Nasdaq Biotechnology Index Fund in the 1st quarter valued at $267,000. State of Tennessee Treasury Department acquired a new position in shares of iShares Nasdaq Biotechnology Index Fund in the 1st quarter valued at $2,053,000. Finally, Analyst IMS Investment Management Services Ltd. lifted its stake in shares of iShares Nasdaq Biotechnology Index Fund by 17.8% in the 1st quarter. Analyst IMS Investment Management Services Ltd. now owns 3,874 shares of the financial services provider’s stock valued at $1,137,000 after purchasing an additional 585 shares during the last quarter. 57.87% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Traders Buy High Volume of iShares Nasdaq Biotechnology Index Fund Put Options (IBB)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/05/traders-buy-high-volume-of-ishares-nasdaq-biotechnology-index-fund-put-options-ibb.html.

About iShares Nasdaq Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with MarketBeat.com's FREE daily email newsletter.